[{"id":"a8dbbb89-8bb1-4f12-ad96-eb67e83dce09","acronym":"","url":"https://clinicaltrials.gov/study/NCT00265798","created_at":"2021-01-18T00:54:12.869Z","updated_at":"2025-02-25T13:47:55.628Z","phase":"Phase 2","brief_title":"Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate","source_id_and_acronym":"NCT00265798","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KIT","pipe":" | ","alterations":" KIT expression","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • imatinib • sunitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 09/14/2005","start_date":" 09/14/2005","primary_txt":" Primary completion: 02/11/2010","primary_completion_date":" 02/11/2010","study_txt":" Completion: 03/08/2025","study_completion_date":" 03/08/2025","last_update_posted":"2025-02-20"},{"id":"8edf0eb7-d0e0-49b2-b787-cd7e18808b64","acronym":"","url":"https://clinicaltrials.gov/study/NCT02597946","created_at":"2021-01-18T12:36:41.049Z","updated_at":"2025-02-25T14:00:49.865Z","phase":"Phase 2","brief_title":"Afatinib in NSCLC With HER2 Mutation","source_id_and_acronym":"NCT02597946","lead_sponsor":"Boehringer Ingelheim","biomarkers":" HER-2 • KIT","pipe":" | ","alterations":" HER-2 mutation","tags":["HER-2 • KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 03/18/2016","start_date":" 03/18/2016","primary_txt":" Primary completion: 07/22/2018","primary_completion_date":" 07/22/2018","study_txt":" Completion: 07/22/2018","study_completion_date":" 07/22/2018","last_update_posted":"2025-02-19"},{"id":"65a39e57-0fe4-43a3-8e14-9aae8f76d3a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06124157","created_at":"2023-11-09T16:12:44.229Z","updated_at":"2025-02-25T14:42:30.057Z","phase":"Phase 3","brief_title":"A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)","source_id_and_acronym":"NCT06124157","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • KIT • PDGFRA • CD19 • PDGFRB • CSF1R","pipe":" | ","alterations":" CD19 expression","tags":["ABL1 • KIT • PDGFRA • CD19 • PDGFRB • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Starasid (cytarabine ocfosfate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 680","initiation":"Initiation: 05/29/2025","start_date":" 05/29/2025","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2025-02-14"},{"id":"39be432b-e1d2-4ded-8099-18c4960548fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06805825","created_at":"2025-02-25T15:15:39.171Z","updated_at":"2025-02-25T15:15:39.171Z","phase":"Phase 1","brief_title":"A Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced And/or Metastatic Solid Tumors Known to Express C-Kit","source_id_and_acronym":"NCT06805825","lead_sponsor":"Novelty Nobility, Inc.","biomarkers":" KIT","pipe":"","alterations":" ","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NN3201"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 02/03/2025","start_date":" 02/03/2025","primary_txt":" Primary completion: 08/30/2027","primary_completion_date":" 08/30/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-13"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"67176e4e-5f06-435a-a426-189730ad7d5a","acronym":"LITESPARK-015","url":"https://clinicaltrials.gov/study/NCT04924075","created_at":"2021-07-05T17:36:40.354Z","updated_at":"2025-02-25T15:26:55.556Z","phase":"Phase 2","brief_title":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)","source_id_and_acronym":"NCT04924075 - LITESPARK-015","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" KIT • PDGFRA • VHL • EPAS1","pipe":" | ","alterations":" PDGFRA mutation","tags":["KIT • PDGFRA • VHL • EPAS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Welireg (belzutifan)"],"overall_status":"Recruiting","enrollment":" Enrollment 322","initiation":"Initiation: 08/12/2021","start_date":" 08/12/2021","primary_txt":" Primary completion: 06/04/2029","primary_completion_date":" 06/04/2029","study_txt":" Completion: 06/04/2029","study_completion_date":" 06/04/2029","last_update_posted":"2025-02-11"},{"id":"7ae66fef-a243-4d8f-b364-a73eb3507cdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04633122","created_at":"2021-01-19T20:36:54.322Z","updated_at":"2025-02-25T15:34:48.949Z","phase":"Phase 2","brief_title":"A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib","source_id_and_acronym":"NCT04633122","lead_sponsor":"Zai Lab (Shanghai) Co., Ltd.","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • Qinlock (ripretinib)"],"overall_status":"Completed","enrollment":" Enrollment 108","initiation":"Initiation: 11/25/2020","start_date":" 11/25/2020","primary_txt":" Primary completion: 07/20/2022","primary_completion_date":" 07/20/2022","study_txt":" Completion: 07/20/2022","study_completion_date":" 07/20/2022","last_update_posted":"2025-02-10"},{"id":"e0869b70-da93-469e-910d-a5ac1a29c3a4","acronym":"LENVAGIST","url":"https://clinicaltrials.gov/study/NCT04193553","created_at":"2025-09-06T15:32:52.730Z","updated_at":"2025-09-06T15:32:52.730Z","phase":"Phase 2","brief_title":"Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure","source_id_and_acronym":"NCT04193553 - LENVAGIST","lead_sponsor":"Centre Leon Berard","biomarkers":" KIT","pipe":"","alterations":" ","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 77","initiation":"Initiation: 01/17/2020","start_date":" 01/17/2020","primary_txt":" Primary completion: 01/30/2024","primary_completion_date":" 01/30/2024","study_txt":" Completion: 04/26/2024","study_completion_date":" 04/26/2024","last_update_posted":"2024-06-18"},{"id":"ddcdaa98-710f-4836-a6b4-89e5e80022ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT05957367","created_at":"2023-07-24T15:08:40.775Z","updated_at":"2024-07-02T16:34:59.920Z","phase":"Phase 1/2","brief_title":"A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies","source_id_and_acronym":"NCT05957367","lead_sponsor":"Deciphera Pharmaceuticals LLC","biomarkers":" BRAF • KIT • PDGFRA","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • KIT mutation • KIT exon 11 mutation • PDGFRA mutation","tags":["BRAF • KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • KIT mutation • KIT exon 11 mutation • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Braftovi (encorafenib) • Qinlock (ripretinib) • inlexisertib (DCC-3116)"],"overall_status":"Recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 09/28/2023","start_date":" 09/28/2023","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-05-31"},{"id":"9f4d4138-2575-46b3-8cf6-894603dcfc63","acronym":"","url":"https://clinicaltrials.gov/study/NCT04908176","created_at":"2021-06-01T17:53:25.780Z","updated_at":"2024-07-02T16:35:07.927Z","phase":"Phase 1","brief_title":"A Drug-drug Interaction Study of Avapritinib and Midazolam","source_id_and_acronym":"NCT04908176","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 08/24/2022","start_date":" 08/24/2022","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 04/12/2024","study_completion_date":" 04/12/2024","last_update_posted":"2024-04-23"},{"id":"46bd478e-b8d0-4e9c-a5fd-b1d6d75d3215","acronym":"","url":"https://clinicaltrials.gov/study/NCT02975700","created_at":"2021-01-18T14:37:44.830Z","updated_at":"2024-07-02T16:35:10.337Z","phase":"","brief_title":"A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma","source_id_and_acronym":"NCT02975700","lead_sponsor":"Daiichi Sankyo Co., Ltd.","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Turalio (pexidartinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 01/31/2017","start_date":" 01/31/2017","primary_txt":" Primary completion: 08/31/2018","primary_completion_date":" 08/31/2018","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-04-10"},{"id":"f0120f59-10df-43f7-b5bb-987a4f3afad2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05493215","created_at":"2022-08-09T17:04:45.434Z","updated_at":"2024-07-02T16:35:12.164Z","phase":"Phase 2","brief_title":"Imatinib TDM in GIST","source_id_and_acronym":"NCT05493215","lead_sponsor":"Reema A. Patel","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA D842V • PDGFRA mutation","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA D842V • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 03/26/2024","start_date":" 03/26/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-01"},{"id":"0a617e4d-d65e-4f5c-a559-adf45a31c05c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01738139","created_at":"2021-01-18T07:36:17.833Z","updated_at":"2024-07-02T16:35:13.511Z","phase":"Phase 1","brief_title":"Ipilimumab and Imatinib Mesylate in Advanced Cancer","source_id_and_acronym":"NCT01738139","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation • KIT positive","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • imatinib"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 02/19/2013","start_date":" 02/19/2013","primary_txt":" Primary completion: 12/13/2022","primary_completion_date":" 12/13/2022","study_txt":" Completion: 12/13/2023","study_completion_date":" 12/13/2023","last_update_posted":"2024-03-21"},{"id":"bdb1c58a-74c6-4750-9dd9-d9830096d0d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03291444","created_at":"2021-01-18T16:15:39.130Z","updated_at":"2024-07-02T16:35:14.542Z","phase":"Phase 1","brief_title":"CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS","source_id_and_acronym":"NCT03291444","lead_sponsor":"Zhujiang Hospital","biomarkers":" KIT • CD20 • IL6 • CD38 • WT1 • CD22 • CD33 • CD34 • NCAM1 • MME • IL3RA","pipe":" | ","alterations":" CD20 positive","tags":["KIT • CD20 • IL6 • CD38 • WT1 • CD22 • CD33 • CD34 • NCAM1 • MME • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/05/2018","start_date":" 05/05/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-15"},{"id":"c6ca9580-1b4f-4786-bd6d-7874e5540e9b","acronym":"GIST","url":"https://clinicaltrials.gov/study/NCT05661643","created_at":"2022-12-22T14:58:40.763Z","updated_at":"2024-07-02T16:35:14.738Z","phase":"Phase 2","brief_title":"The Efficacy and Safety of Temozolomide in SDH-deficient GIST","source_id_and_acronym":"NCT05661643 - GIST","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • PDGFRA • ANO1","pipe":"","alterations":" ","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/28/2023","start_date":" 06/28/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-03-15"},{"id":"1a19387e-f25a-41bd-b670-cc6fddc92951","acronym":"Nautilus","url":"https://clinicaltrials.gov/study/NCT05340621","created_at":"2022-04-22T14:53:50.824Z","updated_at":"2024-07-02T16:35:15.772Z","phase":"Phase 1/2","brief_title":"NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)","source_id_and_acronym":"NCT05340621 - Nautilus","lead_sponsor":"OnKure, Inc.","biomarkers":" BRAF • NRAS • KIT • NF1 • GNAQ","pipe":" | ","alterations":" NRAS mutation • RAS mutation","tags":["BRAF • NRAS • KIT • NF1 • GNAQ"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • bocodepsin (OKI-179)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 05/11/2022","start_date":" 05/11/2022","primary_txt":" Primary completion: 03/04/2026","primary_completion_date":" 03/04/2026","study_txt":" Completion: 04/04/2026","study_completion_date":" 04/04/2026","last_update_posted":"2024-03-07"},{"id":"7158f3c8-048e-44f4-84c4-9fea0fbb9783","acronym":"","url":"https://clinicaltrials.gov/study/NCT06282978","created_at":"2024-02-29T03:33:45.743Z","updated_at":"2024-07-02T16:35:16.129Z","phase":"Phase 2","brief_title":"Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes","source_id_and_acronym":"NCT06282978","lead_sponsor":"PETHEMA Foundation","biomarkers":" KIT • CD19 • CD38 • PTPRC • NCAM1 • CD27 • CD81","pipe":" | ","alterations":" CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression","tags":["KIT • CD19 • CD38 • PTPRC • NCAM1 • CD27 • CD81"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elrexfio (elranatamab-bcmm)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/23/2023","start_date":" 11/23/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-03-06"},{"id":"afe5eda5-b0b2-4528-9023-e2c1d7118027","acronym":"","url":"https://clinicaltrials.gov/study/NCT05905887","created_at":"2023-06-15T17:08:41.962Z","updated_at":"2024-07-02T16:35:17.151Z","phase":"Phase 2","brief_title":"Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor","source_id_and_acronym":"NCT05905887","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • imatinib • sunitinib • AiTan (rivoceranib) • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 09/06/2023","start_date":" 09/06/2023","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-02-28"},{"id":"e55830f0-b06e-4c54-bab4-91b6f117fa14","acronym":"","url":"https://clinicaltrials.gov/study/NCT04582487","created_at":"2021-01-18T21:51:58.830Z","updated_at":"2024-07-02T16:35:20.351Z","phase":"","brief_title":"Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL","source_id_and_acronym":"NCT04582487","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" KIT • CD8 • CD33 • CD34 • CD5 • ITGAM • ANPEP","pipe":"","alterations":" ","tags":["KIT • CD8 • CD33 • CD34 • CD5 • ITGAM • ANPEP"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 05/19/2021","start_date":" 05/19/2021","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2024-02-07"},{"id":"0bf314c0-3f99-4411-8621-e2f140cb0c09","acronym":"ImadGist","url":"https://clinicaltrials.gov/study/NCT02260505","created_at":"2021-01-18T10:37:12.302Z","updated_at":"2024-07-02T16:35:24.473Z","phase":"Phase 3","brief_title":"Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)","source_id_and_acronym":"NCT02260505 - ImadGist","lead_sponsor":"Centre Leon Berard","biomarkers":" KIT","pipe":"","alterations":" ","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Completed","enrollment":" Enrollment 136","initiation":"Initiation: 12/24/2014","start_date":" 12/24/2014","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2024-01-05"},{"id":"0eefbaf9-a4ea-454b-868c-1b99280a8dd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01541709","created_at":"2021-01-18T06:30:56.005Z","updated_at":"2024-07-02T16:35:24.757Z","phase":"Phase 2","brief_title":"Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI","source_id_and_acronym":"NCT01541709","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • ANO1","pipe":" | ","alterations":" KIT mutation • KIT exon 9 mutation","tags":["KIT • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 9 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-01-01"},{"id":"4c2f1c18-6e61-4a09-9dd2-0ccca96142b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03944304","created_at":"2021-01-18T19:25:15.034Z","updated_at":"2024-07-02T16:35:24.855Z","phase":"Phase 2","brief_title":"Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.","source_id_and_acronym":"NCT03944304","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • imatinib • sunitinib • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/27/2019","start_date":" 05/27/2019","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-01-01"},{"id":"7ad2d769-2235-480c-af61-d1fa70b9f998","acronym":"","url":"https://clinicaltrials.gov/study/NCT00255346","created_at":"2021-01-18T00:51:58.980Z","updated_at":"2025-02-25T14:23:55.411Z","phase":"Phase 2","brief_title":"Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)","source_id_and_acronym":"NCT00255346","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KIT","pipe":" | ","alterations":" KIT positive","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 11/15/2005","start_date":" 11/15/2005","primary_txt":" Primary completion: 03/03/2017","primary_completion_date":" 03/03/2017","study_txt":" Completion: 03/03/2017","study_completion_date":" 03/03/2017","last_update_posted":"2023-12-18"},{"id":"bf439f30-e0dc-43f8-a4c4-f4b1f0fa3a26","acronym":"","url":"https://clinicaltrials.gov/study/NCT02571036","created_at":"2021-01-17T17:36:28.986Z","updated_at":"2024-07-02T16:35:26.428Z","phase":"Phase 1","brief_title":"A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies","source_id_and_acronym":"NCT02571036","lead_sponsor":"Deciphera Pharmaceuticals LLC","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation • KIT amplification","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation • KIT amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qinlock (ripretinib)"],"overall_status":"Completed","enrollment":" Enrollment 282","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 04/29/2022","primary_completion_date":" 04/29/2022","study_txt":" Completion: 04/29/2022","study_completion_date":" 04/29/2022","last_update_posted":"2023-12-13"}]